VCYT
Veracyte, Inc.
$42.31
+1.24%
2026-08-21
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Key Fundamentals
P/E Ratio
29.46
Forward P/E
21.17
EPS (TTM)
$1.40
ROE
8.8%
Revenue Growth (YoY)
15.5%
Profit Margin
20.4%
Debt/Equity
2.89
Price/Book
2.50
Beta
1.94
Market Cap
$3.32B
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$60.91
60D Low
$40.10
Avg Volume
1.3M
Latest Close
$42.31
Get breakout alerts for VCYT
Sign up for Breakout Scanner to receive daily notifications when VCYT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Veracyte, Inc. (VCYT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VCYT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VCYT operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.